These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

350 related items for PubMed ID: 2998337

  • 1. Molecular identification and structural requirement of vasoactive intestinal peptide (VIP) receptors in the human colon adenocarcinoma cell line, HT-29.
    Couvineau A, Rousset M, Laburthe M.
    Biochem J; 1985 Oct 01; 231(1):139-43. PubMed ID: 2998337
    [Abstract] [Full Text] [Related]

  • 2. Covalent cross-linking of vasoactive intestinal peptide (VIP) to its receptor in intact colonic adenocarcinoma cells in culture (HT 29).
    Muller JM, Luis J, Fantini J, Abadie B, Giannellini F, Marvaldi J, Pichon J.
    Eur J Biochem; 1985 Sep 02; 151(2):411-7. PubMed ID: 2992966
    [Abstract] [Full Text] [Related]

  • 3. Molecular characteristics and peptide specificity of vasoactive intestinal peptide receptors from rat cerebral cortex.
    Couvineau A, Gammeltoft S, Laburthe M.
    J Neurochem; 1986 Nov 02; 47(5):1469-75. PubMed ID: 3020175
    [Abstract] [Full Text] [Related]

  • 4. The rat liver vasoactive intestinal peptide binding site. Molecular characterization by covalent cross-linking and evidence for differences from the intestinal receptor.
    Couvineau A, Laburthe M.
    Biochem J; 1985 Jan 15; 225(2):473-9. PubMed ID: 3977841
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Molecular identification of receptors for vasoactive intestinal peptide in rat intestinal epithelium by covalent cross-linking. Evidence for two classes of binding sites with different structural and functional properties.
    Laburthe M, Breant B, Rouyer-Fessard C.
    Eur J Biochem; 1984 Feb 15; 139(1):181-7. PubMed ID: 6321173
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Pharmacology, molecular identification and functional characteristics of vasoactive intestinal peptide receptors in human breast cancer cells.
    Gespach C, Bawab W, de Cremoux P, Calvo F.
    Cancer Res; 1988 Sep 15; 48(18):5079-83. PubMed ID: 2842044
    [Abstract] [Full Text] [Related]

  • 11. Cycle of the vasoactive intestinal peptide and its binding site in a human adenocarcinoma cell line (HT 29).
    Luis J, Muller JM, Abadie B, Martin JM, Marvaldi J, Pichon J.
    Eur J Biochem; 1986 May 02; 156(3):631-6. PubMed ID: 3009188
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Characterization of a common VIP-PACAP receptor in human small intestinal epithelium.
    Salomon R, Couvineau A, Rouyer-Fessard C, Voisin T, Lavallée D, Blais A, Darmoul D, Laburthe M.
    Am J Physiol; 1993 Feb 02; 264(2 Pt 1):E294-300. PubMed ID: 8383439
    [Abstract] [Full Text] [Related]

  • 14. Vasoactive intestinal peptide effects on GH3 pituitary tumor cells: high affinity binding, affinity labeling, and adenylate cyclase stimulation. Comparison with peptide histidine isoleucine and growth hormone-releasing factor.
    Wood CL, O'Dorisio MS, Vassalo LM, Malarkey WB, O'Dorisio TM.
    Regul Pept; 1985 Nov 07; 12(3):237-48. PubMed ID: 3001842
    [Abstract] [Full Text] [Related]

  • 15. Receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide in turkey cerebral cortex: characterization by [125I]-VIP binding and effects on cyclic AMP synthesis.
    Zawilska JB, Niewiadomski P, Nowak JZ.
    Gen Comp Endocrinol; 2004 Jun 07; 137(2):187-95. PubMed ID: 15158130
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. A human melanoma-derived cell line (IGR39) with a very high number of vasoactive-intestinal-peptide (VIP) receptors. 1. Molecular characterization of the binding site.
    Luis J, Martin JM, el Battari A, Reynier M, Marvaldi J, Pichon J.
    Eur J Biochem; 1989 Mar 15; 180(2):429-33. PubMed ID: 2538330
    [Abstract] [Full Text] [Related]

  • 20. Characterisation of a high-affinity VIP receptor in human lung parenchyma.
    Schachter M, Dickinson KE, Miles CM, Sever PS.
    FEBS Lett; 1986 Apr 07; 199(1):125-9. PubMed ID: 3007215
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.